Anti-ISCU抗体[OTI4F5]

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ISCU antibody [OTI4F5] (AB180532)

Paraffin-embedded human pancreas carcinoma tissue stained for ISCU with ab180532 at a 1/150 dilution in immunohistochemical analysis. Heat-induced epitope retrieval by 10 mM citric buffer, pH 6.0, 120°C for 3 minutes.

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ISCU antibody [OTI4F5] (AB180532)

Paraffin-embedded human thyroid carcinoma tissue stained for ISCU with ab180532 at a 1/150 dilution in immunohistochemical analysis. Heat-induced epitope retrieval by 10 mM citric buffer, pH 6.0, 120°C for 3 minutes.

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-ISCU antibody [OTI4F5] (AB180532)

Paraffin-embedded human lymphoma tissue stained for ISCU with ab180532 at a 1/150 dilution in immunohistochemical analysis. Heat-induced epitope retrieval by 10 mM citric buffer, pH 6.0, 120°C for 3 minutes.

• WB

Supplier Data

Western blot - Anti-ISCU antibody [OTI4F5] (AB180532)

All lanes:

Western blot - Anti-ISCU antibody [OTI4F5] (ab180532) at 1/2000 dilution

Lane 1:

HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) cell lysate transfected with pCMV6-ENTRY control cDNA for 48 hrs at 5 µg

Lane 2:

HEK-293T cell lysate transfected with the pCMV6-ENTRY ISCU cDNA for 48 hrs at 5 µg

Predicted band size: 18 kDa

true

• WB

CiteAb

Western blot - Anti-ISCU antibody [OTI4F5] (AB180532)

ISCU western blot using anti-ISCU antibody [OTI4F5] ab180532. Publication image and figure legend from Viollet, C., Davis, D. A., et al., 2017, PLoS Pathog, PubMed 28046107.

ab180532 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab180532 please see the product overview.

KSHV infection and hypoxia induce miR-210 independently and additively, while miR-210 modulates its target expression, ISCU, in KSHV-infected cells.(A) Data represent miR-210 relative expression in normoxic and hypoxic SLKK and SLK cells. Values are normalized to the average of normoxic SLK controls set to one. Taqman assays demonstrate that hypoxic conditions (1% O2 for 24hrs) up-regulate miR-210 in both KSHV-infected and uninfected cells (P ≤0.01, Student’s t-test). Additionally, Taqman assays show that KSHV infection alone up-regulates miR-210, in both normoxia and hypoxia (*P ≤0.05, Student’s t-test). (B) Analysis of miR-210 expression in normoxic and hypoxic SLKK cells transfected with miR-210 mimics, anti-miR-210 inhibitors or controls using Taqman assays. Bars depict the relative expression of miR-210 compared to normoxic NT controls. NT : No Transfection. (C) qRT-PCR analysis of ISCU transcript in normoxic and hypoxic SLKK cells transfected with miR-210 mimics, anti-miR-210 inhibitors or controls. Values normalized as in (B). NT : No Transfection. (D) Quantitative immunoblot analysis in normoxic and hypoxic SLKK cells transfected with miR-210 mimics, anti-miR-210 inhibitors or controls. (A), (B), (C), and (D) depict the mean ± sem of three independent experiments. *, **, and *** indicate P ≤0.05, P ≤0.01, and P ≤0.001, respectively.

false